ArticleTanaffos2025
When Silica Returns-Erasmus Syndrome, a Rare Entity.
Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Systemic sclerosis (SS) is an autoimmune disease with vascular changes and diffuse tissue fibrosis. Silica exposure is one of the strongest recognized risk factors for the development of systemic sclerosis (relative risk 3.2). The co-occurrence of systemic sclerosis in a patient with silica exposure is termed Erasmus Syndrome. Few case reports are available in the literature. Case presentation: We report here a case of Erasmus syndrome in a 54-year-old stone worker. The patient presented with diffuse skin thickening, hyperpigmentation, Raynaud's phenomenon, and arthralgia along with radiological features of silicosis. Serological markers of systemic sclerosis were strongly positive, and skin biopsy confirmed scleroderma. Hence, a diagnosis of Erasmus syndrome was made. The clinical, serological, and histopathological features of SA-SS in the patient were indistinguishable from those of idiopathic SS; however, a history of silica dust exposure and evidence of silicosis supported the diagnosis of SA-SS. Conclusion: Careful screening should be done in patients with silicosis along with systemic manifestations to rule out any associated connective tissue disorder. A detailed exposure history should be carefully obtained for all patients with systemic sclerosis.
Indexed as
Identifiers
42027437PMC13102338What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.